Jupiter Wellness Announces First Patient Dosing for Double-Blinded Placebo Controlled Trial of JW-300 for the Treatment of First Degree Burns

JUPITER, FL / October 19, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), a clinical stage company developing a cannabinoid receptor agonist for the treatment of first degree burns, announced the enrollment and dosing of the first patient in the study. The double-blinded placebo-controlled study will enroll 50 patients with newly diagnosed first degree burns of superficial […]

Jupiter Wellness Provides Shareholder Update on Multiple Clinical & Commercial Milestones

JUPITER, FL / October 7, 2021 / Jupiter Wellness, Inc. (NASDAQ:JUPW), today provided an update on its advancing clinical programs and commercial progress. Commercial: Photocil™ to Launch in Q1 2022 Photocil™ (“Phototherapy in a bottle”), a patented topical Over-the-Counter drug for the treatment of psoriasis and vitiligo is expected to launch in Q1 2022. Photocil […]

Investor Alerts

Get our news

For up-to-date company news delivered straight to your inbox or phone, sign up for Investor Alerts today.

To receive alerts via text message, send JUPW to
 +1 (844) 819-8138